1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow HIV Seropositivity: new trials by email Literature Review of HIV Seropositivity trials Research Report on HIV Seropositivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen Raltegravir, Lamivudine - HIV Seropositivity, HIV Infections | Phase 3 | Terminated | Judit Pich | 17 | 2018-05-03 | 2025-05-18 |
HIV Infections (1)
Blood-Borne Infections (1) · Communicable Diseases (1) · Genital Diseases (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1) · Infections (1) · Lentivirus Infections (1) · RNA Virus Infections (1) · Retroviridae Infections (1) · Sexually Transmitted Diseases (1) · Sexually Transmitted Diseases, Viral (1) · Urogenital Diseases (1) · Virus Diseases (1)
Lamivudine (1) · Raltegravir Potassium (1)
Judit Pich (1)
Spain (1)
2017 (1)